!! Products and documentation listed and referenced here are not available to customers within the United States.

At Epigenomics we set ourselves the goal to develop innovative molecular diagnostic tests that address unmet needs in cancer screening and diagnosis. Our key product Epi proColon is a blood test for colorectal cancer based on our proprietary biomarker ^mSEPT9 that can easily be integrated into an annual physical
check-up at the family doctor’s office. Epi proColon, is available as a CE-marked test kit in Europe since October 2009.
We believe that this test has the potential to address the fundamental dilemma in colorectal cancer management. Because the lack of acceptance of currently available screening modalities among average risk individuals aged 50 and above, the target group for population wide colorectal cancer
screening is high. 

Our development pipeline includes Epi proLung, a diagnostic tests for lung cancer that we expect to launch in the first half of 2010 and further tests for screening, diagnosis, and prognosis of colorectal, lung and prostate cancer.


Product Pipeline >>